Antidepressants for the treatment of depression in neurological disorders: A systematic review and meta-analysis of randomised controlled trials

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 82, Issue 8, 2011, Pages 914-923

  Price, Annabel ^a   Rayner, Lauren ^a   Okon Rocha, Ewa ^a   Evans, Alison ^a   Valsraj, Koravangattu ^a   Higginson, Irene J ^a   Hotopf, Matthew ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CITALOPRAM; DESIPRAMINE; FLUOXETINE; MIRTAZAPINE; NOMIFENSINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

BRAIN INJURY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COCHRANE LIBRARY; COGNITION; CONSTIPATION; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; EMBASE; EPILEPSY; FUNCTIONAL STATUS; HUMAN; HYPOTENSION; INSOMNIA; MEDLINE; META ANALYSIS; MULTIPLE SCLEROSIS; NAUSEA; NEUROLOGIC DISEASE; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCINFO; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SEXUAL DYSFUNCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS; COGNITION; DEPRESSION; HUMANS; NERVOUS SYSTEM DISEASES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79960135408     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2010.230862     Document Type: Review

References (43)

1. Raskind MA. Diagnosis and treatment of depression comorbid with neurologic disorders. Am J Med 2008;121(11 Suppl 2):S28-37.
2. Gilliam FG. Diagnosis and treatment of mood disorders in persons with epilepsy. Curr Opin Neurol 2005;18:129-33. (Pubitemid 40477487)
3. Hays RD, Wells KB, Sherbourne CD, et al. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry 1995;52:11-19.
4. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000;160:2101-7. (Pubitemid 30482715)
5. Boulanger L, Zhao Y, Bao Y, et al. A retrospective study on the impact of comorbid depression or anxiety on healthcare resource use and costs among diabetic neuropathy patients. BMC Health Serv Res 2009;9:111.
6. House A, Knapp P, Bamford J, et al. Mortality at 12 and 24 months after stroke may be associated with depressive symptoms at 1 month. Stroke 2001;32:696-701.
7. Rayner L, Price A, Evans A, et al. Antidepressants for depression in physically ill people. Cochrane Database Syst Rev 2010;3:CD007503. doi:10.1002/14651858.CD007503.pub2.
8. Hackett ML, Anderson CS, House A, et al. Interventions for treating depression after stroke. Cochrane Database of Syst Rev 2008;4:CD003437. doi:10.1002/14651858.CD003437.pub3.
9. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002.
10. Chung TH, Deane KH, Ghazi-Noori S, et al. Systematic review of antidepressant therapies in Parkinson's disease. Parkinsonism Relat Disord 2003;10:59-65. (Pubitemid 37476308)
11. Rickards H. Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke. J Neurol Neurosurg Psychiatry 2005;76(Suppl 1):i48-52.
12. Rickards H. Depression in neurological disorders: an update. Curr Opin Psychiatry 2006;19:294-8. (Pubitemid 44309488)
13. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6:e1000097.
14. APA. Diagnostic and statistical manual of mental disorders (DSM IV). 4 Edn. Washington DC: American Psychiatric Association, 1994.
15. WHO. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines: Geneva: World Health Organisation, 1992.
16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
17. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9. (Pubitemid 9136500)
18. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361-70. (Pubitemid 13098606)
19. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008;22:343-96.
20. Furlan AD, Pennick V, Bombardier C, et al. Updated method guidelines for systematic reviews in the Cochrane collaboration back review group. Spine 2003;28:1290-9. (Pubitemid 36734620)
21. Furukawa TA, Barbui C, Cipriani A, et al. Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol 2006;59:7-10. (Pubitemid 41797469)
22. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994;25:1099-104. (Pubitemid 24164745)
23. Fruehwald S, Gatterbauer E, Rehak P, et al. Early fluoxetine treatment of post-stroke depression - a three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol 2003;250:347-51. (Pubitemid 36399276)
24. Lipsey JR, Robinson RG, Pearlson GD, et al. Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet 1984;1:297-300. (Pubitemid 14185332)
25. Murray V, von Arbin M, Bartfai A, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. J Clin Psychiatry 2005;66:708-16. (Pubitemid 40942416)
26. Raffaele R, Rampello L, Vecchio I, et al. Trazodone therapy of post stroke depression. Arch Gerontol Geriatr 1996;5:217-20.
27. Rampello L, Alvano A, Chiechio S, et al. An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression. A random, placebo-controlled study. Arch Gerontol Geriatr 2005;40:275-85.
28. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000;157:351-9. (Pubitemid 30145919)
29. Wiart L, Petit H, Joseph PA, et al. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 2000;31:1829-32. (Pubitemid 30620458)
30. Yang JZY, Bai S. Controlled study on antidepressant treatment of patients with post-stroke depression. Chin Ment Health J 2002;16:871-2.
31. Ponzio F. An 8-week, double-blind, placebo controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from depression following stroke. GlaxoSmithKline Clinical Study Register, 2001. http://www.gskclinicalstudyregister.com/files/pdf/1910.pdf (accessed 17 Jun 2009).
32. Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008;23:850-7.
33. Leentjens AF, Vreeling FW, Luijckx GJ, et al. SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr Psychiatry 2003;18:552-4. (Pubitemid 36763664)
34. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72:886-92.
35. Weintraub D, Mavandadi S, Horn S, et al. Atomoxetine for the treatment of depression in Parkinson's disease: a randomised, double-blind, placebo-controlled study. Research abstract: Am Assoc Geriatr Psychiatry 6 March, Honolulu, Hawaii, 2009.
36. Weiser R, Hernaandez-Rojas J, Flores J, et al. Efficacy, tolerability and safety of mirtazapine in the treatment of major depressive disorder due to Parkinson's disease. Research abstract: International Society for Affective Disorders, Cancun, Mexico, 5-10 March 2004.
37. Wermuth L, Sorensen PS, Timm S, et al. Depression in idiopathic Parkinson's disease treated with citalopram: a placebo controlled trial. Nord J Psychiatry 1998;52:163-9. (Pubitemid 28310706)
38. Ehde DM, Kraft GH, Chwastiak L, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry 2008;30:40-8. (Pubitemid 350299496)
39. Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry 1990;147:1493-7. (Pubitemid 20365439)
40. Ashman TA, Cantor JB, Gordon WA, et al. A randomized controlled trial of sertraline for the treatment of depression in persons with traumatic brain injury. Arch Phys Med Rehabil 2009;90:733-40.
41. Robertson MM, Trimble MR. The treatment of depression in patients with epilepsy. A double-blind trial. J Affect Disord 1985;9:127-36. (Pubitemid 16240197)
42. Arroll B, Elley CR, Fishman T, et al. Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev 2009;3:CD007954.
43. Marquis P, Arnould B, Acquadro C, et al. Patient-reported outcomes and health-related quality of life in effectiveness studies: pros and cons. Drug Dev Res 2006;67:193-201. (Pubitemid 44099979)